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pneumonia, 14.7 for Hib cellulitis, 2.7 for Hib arthritis, 1.3 for Hib other invasive disease, 31 for paralytic poliomyelitis, 10,641 for measles, 6,205 for mumps, 3,300 for rubella and 9,839 for varicella.
The annual incidence of disease per 100,000 population with vaccination was estimated to be 0.001 for diphtheria, 0.015 for tetanus, 33 for pertussis, 0.1 for Hib meningitis, 0.004 for Hib epiglottis, 0.05 for Hib septicaemia, 0.05 for Hib pneumonia, 0.009 for Hib cellulitis, 0.004 for Hib arthritis, 0.05 for Hib other invasive disease, 0 for paralytic poliomyelitis, 1 for measles, 7 for mumps, 0.2 for rubella and 1,091 for varicella.
The probabilities of adverse events per 100,000 doses of vaccine were as follows.
With the DTaP vaccine: 8 for hypotonic hyporesponsive episodes, 10 for uncomplicated seizures, 63 for protracted crying or screaming, and 2 for anaphylaxis.
With the Hib vaccine: 2000 for fever.
With the MMR vaccine: 50 for additional outpatients visits for minor reactions, 1,600 for parotitis, 1,000 for arthralgia or arthritis, 33 for febrile seizures, 3 for thrombocytopenic purpura, and 0.1 for anaphylaxis, aseptic meningitis and encephalitis.
With the Varicella vaccine: 2,000 for rash. 1,000 for additional outpatient visits, 0.2 for pneumonia, and 1.4 for Herpes zoster.
Methods used to derive estimates of effectiveness
The authors used several assumptions to supplement their review.
Estimates of effectiveness and key assumptions
The assumptions were too numerous to report here. The reader is referred to the original paper for further details.
Measure of benefits used in the economic analysis
The measures of health benefit were the number of infected cases prevented and deaths saved by the vaccination programme. These were estimated from the decision tree model. The benefits were discounted at a rate of 3% per annum.
Direct costs
The authors reported the resource use quantities and the costs separately. The study included direct public and private health care costs, and direct patient and relative costs. These comprised the costs of vaccination (e.g. distribution, administration, care-giver time and travel), treatment (e.g. inpatient and outpatient costs) for infections and any sequelae of diseases, and complications. Vaccine prices were obtained from a published pricing list. The source of many of the other unit costs was unclear, as the cost data were derived from published studies. In addition, assumptions were made to assess some cost components. Some of the unit costs were based on charge data. The costs were discounted at a rate of 3% per annum. The study reported the total costs. The method used to inflate costs to the price year 2001 was not reported.
Statistical analysis of costs
Patient level data were not available, thus a statistical analysis of the costs was not relevant.
Indirect Costs
The indirect costs were included in the analysis, which was appropriate given the societal perspective. The indirect costs included productivity losses due to premature morbidity, indirect costs arising from permanent disability, and the opportunity cost of work missed by caregivers. The quantity and cost data were derived from published studies, the
